Summary
Background
The aromatase inhibitors (AIs) are increasingly surpassing tamoxifen as the endocrine treatment of choice for postmenopausal breast cancer patients. With their increasing use, there is concern that they are being inadvertently prescribed to pre- and peri-menopausal women.
Methods
As part of a continuing medical education program for 264 practicing surgeons, a 15-min lecture was given over viewing hormone therapy for early stage breast cancer. Two multi-choice questions were asked before and after the lecture regarding the optimal hormonal treatment for pre and postmenopausal women.
Results
For the optimal treatment of premenopausal women, 36% of respondents chose tamoxifen before the lecture, rising to 82% after it (p<0.01). However 37% suggested an AI would be best, with a further 27% choosing either an AI or tamoxifen, falling to 7% and 11% respectively after the lecture.
Before the lecture, 30% of the participants stated that any of the listed treatment options; tamoxifen alone, an AI alone or a combination of tamoxifen and an AI would be acceptable for postmenopausal women. Following the lecture, 53% chose this option (p<0.01).
Conclusions
In many countries it is practicing surgeons who commence endocrine therapy for patients with breast cancer. The findings of this study are useful from two points. Firstly it is clear that many physicians feel that AIs are an effective adjuvant endocrine therapy for premenopausal breast cancer. Secondly it demonstrates the benefits of continuing medical education as a significant improvement in test scores was noted after a structured lecture.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Clemons MJ, Goss PE, Estrogen exposure and breast cancer riskN Eng J Med2001; 344(4): 276–285
Clarke M, Collins R, Darby S, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomized trials Lancet2005; 9472: 1687–1717
Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study GroupJ Clin Oncol2000; 18:3758–3767
Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability studyJ Clin Oncol2000; 18:3748–3757
Mouridsen H, Sun Y, Gershanovich M, et al. Final survival analysis of the double blind, randomized, multinational phase III trial of letrozole compared to tamoxifen as first line hormonal therapy for advanced breast cancerBreast Cancer Res Treat2001; 69:211
Coombes C, Hall E, Gibson L, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerN Engl J Med 2004; 350:1081–1092
Goss P, Ingle J, Martino S, et al. A randomized trial of letrozole in post - menopausal women after five years of tamoxifen therapy for early stage breast cancer N Engl J Med2003; 349:1793–1802
Howell A Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet2005, 365:60–62
Jakesz R, Kaufmann M, Gnant M, et al. Benefits of switching postmenopausal women with hormone sensitive early breast cancer to anastrazole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat2004; 88:Abstract 2
BIG 1–98 Collaborative Group. Letrozole vs Tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer, BIG 1–98: A prospective randomized double blind phase III study. Breast 2005; 14: S4
Winer EP, Hudis C, Burstein HJ, et al.: American Society of Clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor positive breast cancer: Status reports 2004. J␣Clin Oncol 2005, epub ahead of print 10.1200/JCO.2005.09.121
Goss PE, Strasser K, Aromatase inhibitors in the treatment and prevention of breast cancer J Clin Oncol2001; 19(3):881–894
Clemons M, Coleman RE, Verma S, Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?Cancer Treat Rev2004; 30(4):325–332
Author information
Authors and Affiliations
Corresponding author
Additional information
An Erratum for this article can be found at http://dx.doi.org/10.1007/s10549-006-9165-4
Rights and permissions
About this article
Cite this article
Gainford, M., McCready, D., Cohen, Z. et al. The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer. Breast Cancer Res Treat 96, 203–206 (2006). https://doi.org/10.1007/s10549-005-9031-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-005-9031-9